{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:11Z","timestamp":1786994411713,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.msard.2022.104472","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T17:20:20Z","timestamp":1671384020000},"page":"104472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis"],"prefix":"10.1016","volume":"70","author":[{"given":"Regina","family":"Berkovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Negroski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen G.","family":"Bzdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex L.","family":"Lublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea M.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuc","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danelle P.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Dumlao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Bora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Ranno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le H.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104472_bib0001","unstructured":"European Medicines Agency (2017). \"European medicines agency's annual report 2017.\" Retrieved July 27, 2022, 2022, from https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/2017-annual-report-european-medicines-agency_en.pdf."},{"key":"10.1016\/j.msard.2022.104472_bib0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2017.12.003","article-title":"Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count","volume":"20","author":"Baharnoori","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2022.104472_bib0003","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2022.104472_bib0004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.msard.2017.07.007","article-title":"Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report","volume":"17","author":"Berkovich","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2022.104472_bib0005","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1007\/s10072-021-05145-x","article-title":"Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study","volume":"42","author":"Brecl Jakob","year":"2021","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2022.104472_bib0006","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.104472_bib0007","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11940-021-00662-8","article-title":"Treating MS after 50: the role of age in therapeutic decision-making","volume":"23","author":"Hua","year":"2021","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2022.104472_bib0008","article-title":"Progressive motor impairment from \"critical\" demyelinating lesions of the cervicomedullary junction","author":"Jackson-Tarlton","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104472_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211005588","article-title":"Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status","volume":"14","author":"Kallmann","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.msard.2022.104472_bib0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/nmt-2021-0014","article-title":"An updated review of teriflunomide's use in multiple sclerosis","volume":"11","author":"Miller","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"issue":"10","key":"10.1016\/j.msard.2022.104472_bib0011","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.104472_bib0012","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/acn3.534","article-title":"Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study","volume":"5","author":"Miller","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"14","key":"10.1016\/j.msard.2022.104472_bib0013","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2022.104472_bib0014","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","article-title":"A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses","volume":"66","author":"O'Connor","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104472_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211028781","article-title":"Efficacy and safety of teriflunomide in multiple sclerosis across age groups: analysis from pooled pivotal and real-world studies","volume":"13","author":"Oh","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.msard.2022.104472_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102944","article-title":"Multiple sclerosis hospitalizations among users of oral disease-modifying therapies","volume":"52","author":"Pham Nguyen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2022.104472_bib0017","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1212\/NXI.0000000000000390","article-title":"Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA","volume":"4","author":"Radue","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"10","key":"10.1016\/j.msard.2022.104472_bib0018","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1177\/1352458519855722","article-title":"Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide","volume":"26","author":"Sprenger","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104472_bib0019","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neubiorev.2019.12.027","article-title":"The need to incorporate aged animals into the preclinical modeling of neurological conditions","volume":"109","author":"Sun","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"6","key":"10.1016\/j.msard.2022.104472_bib0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.104472_bib0021","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2022.104472_bib0022","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2022.104472_bib0023","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1212\/WNL.0000000000004885","article-title":"Effects of physical comorbidities on disability progression in multiple sclerosis","volume":"90","author":"Zhang","year":"2018","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:06:27Z","timestamp":1761901587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822009762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":23,"alternative-id":["S2211034822009762"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104472","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104472"}}